Across TCGA pan-cancer cohorts, SRGAP2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SRGAP2B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher SRGAP2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRGAP2B expression acts as an unfavorable survival marker.

LGG, UCEC, and LIHC are the cancer types where SRGAP2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.250	0.753	.020	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.093	0.543	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SRGAP2B tumor-vs-normal RNA expression · all SRGAP2B data types